- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05609630
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (SELECT-sJIA)
A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to < 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide.
Participants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits/calls during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Medical Centre /ID# 251691
-
Parkville, Victoria, Australia, 3052
- Recruiting
- Royal Children's Hospital /ID# 251663
-
-
-
-
-
Sao Paulo, Brazil, 05403-000
- Recruiting
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 251764
-
-
-
-
Chongqing
-
Chongqing, Chongqing, China, 400065
- Recruiting
- The Children's Hospital of Chongqing Medical University /ID# 251539
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215025
- Recruiting
- Children's Hospital of Soochow University /ID# 251755
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710054
- Recruiting
- Xi'an Children's Hospital /ID# 251693
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Children's Hospital of Fudan University /ID# 251619
-
-
-
-
-
Hamburg, Germany, 22081
- Recruiting
- Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 251564
-
Sankt Augustin, Germany, 53757
- Recruiting
- Asklepios Klinik Sankt Augustin /ID# 251565
-
-
-
-
Firenze
-
Florence, Firenze, Italy, 50139
- Recruiting
- Azienda Ospedaliero Universitaria Meyer /ID# 251775
-
-
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan, 650-0047
- Recruiting
- Hyogo Prefectural Kobe Children's Hospital /ID# 251649
-
Contact:
- Site Coordinator
- Phone Number: +81-78-945-7300
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Japan, 216-8511
- Recruiting
- St. Marianna University Hospital /ID# 251623
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 951-8520
- Recruiting
- Niigata University Medical & Dental Hospital /ID# 251538
-
-
Osaka
-
Takatsuki-shi, Osaka, Japan, 569-8686
- Recruiting
- Osaka Medical and Pharmaceutical University Hospital /ID# 252092
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8519
- Recruiting
- Tokyo Medical And Dental University Hospital /ID# 251505
-
-
-
-
-
Valencia, Spain, 46026
- Recruiting
- Hospital Universitario y Politecnico La Fe /ID# 251352
-
-
-
-
-
Ankara, Turkey, 06560
- Recruiting
- Gazi University Medical Faculty /ID# 253677
-
Istanbul, Turkey, 34093
- Recruiting
- Istanbul University Istanbul Medical Faculty /ID# 251652
-
Istanbul, Turkey, 34098
- Recruiting
- Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 251651
-
-
-
-
Oregon
-
Portland, Oregon, United States, 97227-1654
- Recruiting
- Randall Children's Hospital /ID# 251829
-
Contact:
- Site Coordinator
- Phone Number: 1-503-413-2150
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Baseline with a total body weight of 10 kg or higher at screening and a diagnosis of systemic juvenile idiopathic arthritis (sJIA) according to International League of Associations for Rheumatology (ILAR) criteria for at least 6 weeks prior to Screening, with onset prior to 16 years old, and meet the following conditions:
- Must have active sJIA with at least 2 active joints at Screening and Baseline, fever more than 38°C for any out of 14 consecutive days before the Screening Visit, and an erythrocyte sedimentation rate (ESR) or high-sensitivity C-reactive protein (hsCRP) > 1.5 × upper limit of normal (ULN) at Screening. OR At least 5 active joints at Screening and Baseline and an ESR or hsCRP > 1.5 × ULN at Screening.
- Must have inadequate response to previous treatment with nonsteroidal anti-inflammatory drugs and systemic glucocorticoids, as judged by the investigator.
- For Cohort 1, participants must not have had previous treatment with any IL-6 inhibitor. For Cohort 2, participants must have an intolerance or inadequate response to an IL-6 inhibitor as judged by the investigator.
Note: For Cohort 1, participants must be ages 2 to < 18 years old in countries where SC tocilizumab is not approved for sJIA.
Exclusion Criteria:
- Must have any type of juvenile idiopathic arthritis (JIA), other than sJIA, as defined by the ILAR criteria, and must not have a history or presence of any other autoimmune inflammatory condition other than sJIA.
- Must have uncontrolled severe systemic disease and/or impeding or active macrophage activation syndrome within 3 months prior to Baseline.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 Upadacitinib
Participants will receive upadacitinib for 52 weeks.
|
Oral tablet or Oral solution
Other Names:
|
Active Comparator: Cohort 1 Tocilizumab
Participants will receive tocilizumab for 52 weeks.
|
Subcutaneous injection or Intravenous infusion
|
Experimental: Cohort 2 Upadacitinib
Participants will receive upadacitinib for 52 weeks.
|
Oral tablet or Oral solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 30 Response
Time Frame: At Week 12
|
ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.
ACR 30 Response is defined as absence of fever [> 38°C] in the previous 1 week preceding evaluation and improvement of ≥ 30% of the 6 variables of the JIA core set with no more than 1 variable worsening by > 30%.
|
At Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 50 Response
Time Frame: Week 12
|
ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.
ACR 50 Response is defined as absence of fever [> 38°C] in the previous 1 week preceding evaluation and improvement of ≥ 50% of the 6 variables of the JIA core set.
|
Week 12
|
Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 70 Response
Time Frame: Week 12
|
ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.
ACR 70 Response is defined as absence of fever [> 38°C] in the previous 1 week preceding evaluation and improvement of ≥ 70% of the 6 variables of the JIA core set.
|
Week 12
|
Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 90 Response
Time Frame: Week 12
|
ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.
ACR 90 Response is defined as absence of fever [> 38°C] in the previous 1 week preceding evaluation and improvement of ≥ 90% of the 6 variables of the JIA core set.
|
Week 12
|
Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 100 Response
Time Frame: Week 12
|
ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.
ACR 100 Response is defined as absence of fever [> 38°C] in the previous 1 week preceding evaluation and improvement of ≥ 100% of the 6 variables of the JIA core set.
|
Week 12
|
Change from Baseline in Number of Joints with Active Arthritis
Time Frame: Week 12
|
Change from Baseline in Number of Joints with Active Arthritis
|
Week 12
|
Change from Baseline in Number of Joints with Limitation of Motion
Time Frame: Week 12
|
Change from Baseline in Number of Joints with Limitation of Motion
|
Week 12
|
Change from Baseline in Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI)
Time Frame: Week 12
|
The CHAQ-DI consists of 30 items and assesses function in 8 areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.
There are 5 response options ranging from no difficulty to unable to do, scored 0 to 3, and not applicable.
|
Week 12
|
Change From Baseline in Patient's Global Assessment (PtGA)
Time Frame: Week 12
|
Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS).
The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity.
Negative values indicate improvement from baseline.
|
Week 12
|
Change From Baseline in Physician's Global Assessment of Disease Activity (PhGA)
Time Frame: Week 12
|
Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS).
The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity.
Negative values indicate improvement from baseline.
|
Week 12
|
Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Time Frame: Week 12
|
High sensitivity C-reactive protein was analyzed by a central laboratory.
The median percent change from baseline in CRP is assessed at each time point.
|
Week 12
|
Percentage of Participants with Absence of fever (> 38°C) Attributed to systemic Juvenile Idiopathic Arthritis (sJIA)
Time Frame: Week 12
|
Absence of fever (> 38°C) Attributed to systemic Juvenile Idiopathic Arthritis (sJIA)
|
Week 12
|
Change from Baseline in Glucocorticoid Dose
Time Frame: Week 12
|
Change from Baseline in Glucocorticoid Dose
|
Week 12
|
Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS27-CRP)
Time Frame: Week 12
|
Juvenile Arthritis Disease Activity Score (JADAS27-CRP) will be assessed
|
Week 12
|
Percentage of Participants Achieving Inactive Disease (ID) Status by Juvenile Arthritis Disease Activity Score (JADAS27)-CRP
Time Frame: Week 12
|
Inactive Disease (ID) status by 27-joint Juvenile Arthritis Disease Activity Score (JADAS27)-CRP will be assessed.
|
Week 12
|
Percentage of Participants Achieving Minimal Disease Activity (MDA) by Juvenile Arthritis Disease Activity Score (JADAS27)-CRP
Time Frame: Week 12
|
Minimal Disease Activity (MDA) by 27-joint Juvenile Arthritis Disease Activity Score (JADAS27)-CRP will be assessed.
|
Week 12
|
Percentage of Participants Achieving Clinical Remission by Juvenile Arthritis Disease Activity Score (JADAS27)-CRP
Time Frame: Week 12
|
Clinical Remission by 27-joint Juvenile Arthritis Disease Activity Score (JADAS27)-CRP will be assessed.
|
Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Juvenile
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Protein Kinase Inhibitors
- Janus Kinase Inhibitors
- Upadacitinib
Other Study ID Numbers
- M14-682
- 2022-501599-25-00 (Other Identifier: EU CT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Idiopathic Arthritis
-
University of AarhusAarhus University HospitalCompletedPolyarticular Juvenile Rheumatoid Arthritis | Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis, OligoarthritisDenmark
-
Institut National de la Santé Et de la Recherche...CompletedSystemic-Onset Juvenile Idiopathic ArthritisFrance
-
GeneScience Pharmaceuticals Co., Ltd.Not yet recruitingActive Systemic Juvenile Idiopathic ArthritisChina
-
Novartis PharmaceuticalsCompletedSystemic Juvenile Idiopathic Arthritis (SJIA)Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic Arthritis With Active FlareUnited States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
-
University of British ColumbiaUniversity of Manitoba; The Hospital for Sick Children; McGill University Health... and other collaboratorsRecruiting
-
AbbVieCompletedPolyarticular Juvenile Idiopathic Arthritis
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile Idiopathic Arthritis (JIA)France
-
AbbVieRecruitingJuvenile Idiopathic Arthritis (JIA)United States, Germany, Hungary, Israel, Puerto Rico, Spain, Japan, Canada, Italy, Sweden
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedJuvenile Idiopathic Arthritis (JIA)United States
Clinical Trials on Upadacitinib
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
AbbVieNot yet recruiting
-
AbbVieNot yet recruiting
-
University Hospital, MontpellierRecruitingRheumatoid ArthritisFrance
-
AbbVieActive, not recruitingUlcerative Colitis (UC)United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic... and more
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Norway, Puerto Rico
-
AbbVieWithdrawn
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Argentina, Australia, Bosnia and Herzegovina, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Italy, Japan, Malaysia, New Zealand, Puerto Rico, Romania, Russian Federation, Sw... and more
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Taiwan, United Kingdom